Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

Patients who have no residual invasive cancer following neoadjuvant chemotherapy for breast carcinoma have a better overall survival than those with residual disease. Many classification systems assessing pathological response to neoadjuvant chemotherapy include residual ductal carcinoma in situ (DC...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, R L, Lakhani, S R, Ring, A E, Ashley, S, Walsh, G, Smith, I E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361141/
https://www.ncbi.nlm.nih.gov/pubmed/16421590
http://dx.doi.org/10.1038/sj.bjc.6602950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361141/
https://www.ncbi.nlm.nih.gov/pubmed/16421590
http://dx.doi.org/10.1038/sj.bjc.6602950

Ejemplares similares